Quantcast

Latest Array BioPharma Inc. Stories

2014-08-12 08:29:26

Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ending June 30, 2014. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Ron Squarer, Chief Executive Officer of Array, noted, "The Array-invented MEK inhibitors, binimetinib and selumetinib, are currently enrolling six Phase 3 trials, and each of our partners has...

2014-07-28 12:28:09

BOULDER, Colo., July 28, 2014 Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Conference Call Information Date: Tuesday,...

2014-06-11 16:26:40

BOULDER, Colo., June 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities 2014 Healthcare Conference in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Event: Wells Fargo Securities 2014 Healthcare Conference Presenter: Ron...

2014-06-02 12:29:47

Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and selumetinib, were showcased at the 50th annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and CDK4/6 inhibitor LEE011 (discovered by Novartis Institutes for BioMedical Research in collaboration with Astex...

2014-05-28 08:33:06

Array to advance kinase inhibitors for inflammatory disease BOULDER, Colo., May 28, 2014 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced today a collaboration agreement with Biogen Idec (NASDAQ: BIIB) for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO The collaboration target and lead inhibitors were discovered through Array's proprietary...

2014-05-27 20:22:10

BOULDER, Colo., May 27, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Jefferies 2014 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Event: Jefferies 2014 Global Healthcare Conference Presenter:...

2014-05-19 16:24:18

Appoints Nicholas A. Saccomano, Ph.D. as Chief Scientific Officer and Robert E. Winkler, M.D. as Vice President of Clinical Development BOULDER, Colo., May 19, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today announced the appointments of Nicholas A. Saccomano, Ph.D., as Chief Scientific Officer and Robert E....

2014-05-14 08:30:37

BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 - June 3, 2014 in Chicago, Illinois. Both MEK inhibitors are advancing in Phase 3 or pivotal trials: binimetinib is being evaluated in NRAS- and BRAF-mutant...

2014-05-13 23:15:05

Corridor Company, a leader in contract management and business-critical applications for SharePoint, is pleased to announce that Array BioPharma has selected Corridor’s Contract Management Business App for SharePoint – CM[.app]™ – as its contract lifecycle management tool. Wakefield, MA (PRWEB) May 13, 2014 Corridor Company, a leader in contract management and business-critical applications for SharePoint, is pleased to announce that Array BioPharma has selected Corridor’s...

2014-05-12 12:31:16

BOULDER, Colo., May 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare Conference in New York City. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related